Press Releases

News from the year: /2013

Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning

Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microsoft Research to improve the yield and quality of next generation gene therapy vectors using the cloud and machine… Read More

Read more

Notice of Preliminary Results

London, UK – 8 February 2019: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, will be announcing its Preliminary Results for the year ended 31 December 2018 on Thursday 14 March 2019. A briefing for analysts will be held at 12:00pm… Read More

Read more

Oxford Biomedica notes Axovant announcement of feedback from FDA regarding AXO-LENTI-PD and progress with ongoing Phase 2 clinical trial

Oxford, UK – 06 December 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, notes an announcement today by Axovant Sciences regarding feedback from a face-to-face pre-IND meeting with the U.S. Food and Drug Administration (FDA) concerning AXO-Lenti-PD for patients with… Read More

Read more

Oxford Biomedica notes the longer-term analyses from pivotal Kymriah® trials, which showed durable responses are maintained in patients with advanced blood cancers

Oxford, UK – 01 December 2018: Oxford Biomedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA and JULIET pivotal trials in children and young adult patients with relapsed or… Read More

Read more